GURUFOCUS.COM » STOCK LIST » Consumer Defensive » Consumer Packaged Goods » JHS Svendgaard Laboratories Ltd (BOM:532771) » Definitions » Capex-to-Revenue

JHS Svendgaard Laboratories (BOM:532771) Capex-to-Revenue : 0.00 (As of Mar. 2024)


View and export this data going back to 2006. Start your Free Trial

What is JHS Svendgaard Laboratories Capex-to-Revenue?

Capex-to-Revenue measures a company's investments in physical assets such as property, industrial buildings or equipment to its revenue.

JHS Svendgaard Laboratories's Capital Expenditure for the three months ended in Mar. 2024 was ₹0.00 Mil. Its Revenue for the three months ended in Mar. 2024 was ₹216.63 Mil.

Hence, JHS Svendgaard Laboratories's Capex-to-Revenue for the three months ended in Mar. 2024 was 0.00.


JHS Svendgaard Laboratories Capex-to-Revenue Historical Data

The historical data trend for JHS Svendgaard Laboratories's Capex-to-Revenue can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

JHS Svendgaard Laboratories Capex-to-Revenue Chart

JHS Svendgaard Laboratories Annual Data
Trend Mar15 Mar16 Mar17 Mar18 Mar19 Mar20 Mar21 Mar22 Mar23 Mar24
Capex-to-Revenue
Get a 7-Day Free Trial Premium Member Only Premium Member Only 0.10 0.08 0.08 0.17 0.45

JHS Svendgaard Laboratories Quarterly Data
Jun19 Sep19 Dec19 Mar20 Jun20 Sep20 Dec20 Mar21 Jun21 Sep21 Dec21 Mar22 Jun22 Sep22 Dec22 Mar23 Jun23 Sep23 Dec23 Mar24
Capex-to-Revenue Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only - - - - -

Competitive Comparison of JHS Svendgaard Laboratories's Capex-to-Revenue

For the Household & Personal Products subindustry, JHS Svendgaard Laboratories's Capex-to-Revenue, along with its competitors' market caps and Capex-to-Revenue data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.


JHS Svendgaard Laboratories's Capex-to-Revenue Distribution in the Consumer Packaged Goods Industry

For the Consumer Packaged Goods industry and Consumer Defensive sector, JHS Svendgaard Laboratories's Capex-to-Revenue distribution charts can be found below:

* The bar in red indicates where JHS Svendgaard Laboratories's Capex-to-Revenue falls into.



JHS Svendgaard Laboratories Capex-to-Revenue Calculation

JHS Svendgaard Laboratories's Capex-to-Revenue for the fiscal year that ended in Mar. 2024 is calculated as

Capex-to-Revenue=- Capital Expenditure / Revenue
=- (-315.326) / 707.982
=0.45

JHS Svendgaard Laboratories's Capex-to-Revenue for the quarter that ended in Mar. 2024 is calculated as

Capex-to-Revenue=- Capital Expenditure / Revenue
=- (0) / 216.634
=0.00

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.


JHS Svendgaard Laboratories  (BOM:532771) Capex-to-Revenue Explanation

Capex-to-Revenue measures a company's investments in physical assets such as property, industrial buildings or equipment to its revenue. The ratio shows how aggressively the company reinvests its revenue back into productive assets. However, a high ratio potentially indicates that the company has invested too much in innovation and infrastructure, taking up funds that could be used to boost productivity and increase revenue. Therefore, a high Capex to Revenue Ratio could be a positive or a negative sign depending on how effectively a company converts those investments into future earnings.


JHS Svendgaard Laboratories Capex-to-Revenue Related Terms

Thank you for viewing the detailed overview of JHS Svendgaard Laboratories's Capex-to-Revenue provided by GuruFocus.com. Please click on the following links to see related term pages.


JHS Svendgaard Laboratories (BOM:532771) Business Description

Traded in Other Exchanges
Address
Mathura Road, B-1/E-23, Mohan Co-operative Industrial Area, New Delhi, IND, 110044
JHS Svendgaard Laboratories Ltd is a manufacturer of dental and oral care products. Its business segments include Manufacturing Business; Other than Manufacturing Business and Retail Business. Its product portfolio includes a toothbrush, toothpaste, mouthwash, laundry detergent, hand sanitizer, and room fresheners. It sells products under its own brand name and private labels including Dr. Gold, P&G, Amway, Future Group, Dabur, Elder Pharma, J. L. Morison's among others, and in the international market are - Dr. Fresh, Boots, Peanuts, and Lavoris. It generates the majority of the revenue from the Manufacturing Business segment.

JHS Svendgaard Laboratories (BOM:532771) Headlines

No Headlines